Abstract 2119P
Background
Malnutrition and weight loss have renowned prognostic value in patients (pts) with localised gastric cancer (GC). We analysed the association of weight loss and early nutritional intervention with outcomes in pts with advanced GC.
Methods
A retrospective cohort of non-resected metastatic GC pts treated with first-line chemotherapy (CT) at the Academic Hospital of Udine (2012-2022) was analysed. Biometric and nutritional parameters were evaluated at diagnosis and during treatment. The prognostic value of >10% weight loss 3 months (mo) after nutritional intervention was assessed. Nutritional interventions and scores (Prognostic Nutritional Index [PNI], neutrophil-lymphocyte ratio [NLR], platelet-lymphocyte ratio [PLR]), dichotomized as high/low per literature-derived cut-offs, were evaluated as predictors of overall survival (OS) and progression-free survival (PFS) with Cox regression model.
Results
100 pts were included (65 male), median age was 69 years. At CT start, 87.8% of pts had lost weight (>10% in 49.4%), with a median loss of 8 Kg. 55.7% of pts had low PNI, more than 60% high NLR and PLR. 71 pts underwent nutritional assessment (NA), 53.5% before CT start; median time from diagnosis to NA was 40 days. 51 pts had >1 NA, 31 pts >2 NA. At first NA, nutritional interventions consisted in oral supplements (53.4%), parenteral nutrition (28.2%) and counselling (59.2%). Overall, 49% of pts gained weight 3 mo after NA; 88.9% of pts’ PNI improved, >50% of NLR and PLR lowered. At disease progression, recorded in 96 pts, PLR and NLR increased significantly (60% vs 48% at 3 mo after NA and 70% vs 34%, respectively). In our cohort, median PFS was 5 mo and median OS was 9 mo. Low PNI (HR 2.05, p = 0.008), high NLR (HR 2.51, p <0.001) and PLR (HR 2.63, p <0.001) at CT start and a >10% weight loss (HR 3.05, p = 0.020) 3 mo after first NA were associated with worse OS. PLR improvement at 3 mo after first NA was associated with better OS (HR 0.46, p = 0.018).
Conclusions
These results underline the importance of early and efficient nutritional assessment and support in cancer pts. The prognostic value of PNI, NLR and PLR reinforces the importance of the interplay between immune system and weight loss for advanced GC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Puglisi: Financial Interests, Research Grant: AstraZeneca, Eisai; Financial Interests, Financially compensated role: AstraZeneca, Roche, Amgen, Lilly, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06